Insider Trading Activity Blueprint Medicines Corp (NASDAQ:BPMC) – Major Shareholder Sold 30,000 shares of Stock

15

Insider Trading Activity For Blueprint Medicines Corp (NASDAQ:BPMC)

Mark J Levin , Major Shareholder of Blueprint Medicines Corp (NASDAQ:BPMC) reportedly Sold 30,000 shares of the company’s stock at an average price of 40.88 for a total transaction amount of $1,226,400.00 SEC Form

Insider Trading History For Blueprint Medicines Corp (NASDAQ:BPMC)

  • On 11/3/2015 Christoph Lengauer, insider, sold 84,998 with an average share price of $21.05 per share and the total transaction amounting to $1,789,207.90. View SEC Filing
  • On 11/17/2015 Fmr Llc, Insider, sold 27,490 with an average share price of $20.60 per share and the total transaction amounting to $566,294.00. View SEC Filing
  • On 11/19/2015 Fmr Llc, Insider, sold 237,218 with an average share price of $19.76 per share and the total transaction amounting to $4,687,427.68. View SEC Filing
  • On 11/23/2015 Fmr Llc, Insider, sold 189,572 with an average share price of $20.15 per share and the total transaction amounting to $3,819,875.80. View SEC Filing
  • On 11/24/2015 Fmr Llc, Insider, sold 161,271 with an average share price of $20.14 per share and the total transaction amounting to $3,247,997.94. View SEC Filing
  • On 11/27/2015 Fmr Llc, Insider, sold 287,415 with an average share price of $21.48 per share and the total transaction amounting to $6,173,674.20. View SEC Filing
  • On 12/17/2015 Christoph Lengauer, insider, sold 31,119 with an average share price of $25.05 per share and the total transaction amounting to $779,530.95. View SEC Filing
  • Analyst Ratings For Blueprint Medicines Corp (NASDAQ:BPMC)
    These are 8 Buy Ratings .
    The current consensus rating for Blueprint Medicines Corp (NASDAQ:BPMC) is Buy (Score: 3.00) with a consensus target price of $38.74 , a potential (6.44% downside)

    Analyst Ratings History For Blueprint Medicines Corp (NASDAQ:BPMC)

    • On 3/9/2016 JPMorgan Chase & Co. Lower Price Target of rating Market Outperform with a price target of $54.00 to $37.00
    • On 5/27/2016 Raymond James Financial, Inc. Initiated Coverage of rating Outperform with a price target of $23.00
    • On 11/12/2016 Canaccord Genuity Set Price Target of rating Buy with a price target of $35.00
    • On 12/1/2016 JMP Securities Reiterated Rating Buy
    • On 12/5/2016 Cowen and Company Reiterated Rating Buy with a price target of $38.33 to $33.19
    • On 12/6/2016 Wedbush Reiterated Rating Outperform with a price target of $43.00
    • On 12/14/2016 Jefferies Group LLC Initiated Coverage of rating Buy with a price target of $40.00

    About Blueprint Medicines Corp (NASDAQ:BPMC)
    Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).

    Recent Trading Activity for Blueprint Medicines Corp (NASDAQ:BPMC)
    Shares of Blueprint Medicines Corp closed the previous trading session at 41.41 up +0.05 0.12% with 281,572 shares trading hands.

    An ad to help with our costs